InterVenn Biosciences Funding & Investors

South San Francisco, CA

InterVenn focuses on the identification, quantification, and classification of Glycoproteomic and other PTM signals found in human blood and tissue for biomarker and target discovery. It specializes in the fields of biotechnology and life science. The company's VISTA is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides. It was founded in 2017 and headquartered in Redwood City, California.